Evidence map›Paper›PMID 34504497›Full record

Trial reportFrontiers in immunology2021

SARS-CoV-2 Spike Protein-Directed Monoclonal Antibodies May Ameliorate COVID-19 Complications in APECED Patients.

Elise M N Ferré, Monica M Schmitt, Sebastian Ochoa, Lindsey B Rosen, Elana R Shaw, Peter D Burbelo, Jennifer L Stoddard, Shakuntala Rampertaap, Tom DiMaggio, Jenna R E Bergerson and 4 more

Open access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. COVID-19 and Inborn Errors of Immunity.Physiology (Bethesda, Md.) · 2022
    Review
  9. Immunizing the imperfect immune system: Coronavirus disease 2019 vaccination in patients with inborn errors of immunity.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2022
    Review
  10. Article
  11. Review
  12. Monoclonal antibody-mediated neutralization of SARS-CoV-2 in an IRF9-deficient child.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Elise M N FerréFungal Pathogenesis Section, LCIM, NIAID, NIH, Bethesda, MD, United States.
Monica M SchmittFungal Pathogenesis Section, LCIM, NIAID, NIH, Bethesda, MD, United States.
Sebastian OchoaFungal Pathogenesis Section, LCIM, NIAID, NIH, Bethesda, MD, United States.
Lindsey B RosenImmunopathogenesis Section, LCIM, NIAID, NIH, Bethesda, MD, United States.
Elana R ShawHuman Immunological Diseases Section, LCIM, NIAID, NIH, Bethesda, MD, United States.
Peter D BurbeloNational Institute of Dental and Craniofacial Research, NIH, Bethesda, MD, United States.
Jennifer L StoddardImmunology Service, Department of Laboratory Medicine, NIH Clinical Center, NIH, Bethesda, MD, United States.
Shakuntala RampertaapImmunology Service, Department of Laboratory Medicine, NIH Clinical Center, NIH, Bethesda, MD, United States.
Tom DiMaggioFungal Pathogenesis Section, LCIM, NIAID, NIH, Bethesda, MD, United States.
Jenna R E BergersonImmune Deficiency Genetics Section, LCIM, NIAID, NIH, Bethesda, MD, United States.
Sergio D RosenzweigImmunology Service, Department of Laboratory Medicine, NIH Clinical Center, NIH, Bethesda, MD, United States.
Luigi D NotarangeloImmune Deficiency Genetics Section, LCIM, NIAID, NIH, Bethesda, MD, United States.
Steven M HollandImmunopathogenesis Section, LCIM, NIAID, NIH, Bethesda, MD, United States.
Michail S LionakisFungal Pathogenesis Section, LCIM, NIAID, NIH, Bethesda, MD, United States.
National Institutes of Health · USNational Institute of Allergy and Infectious Diseases · USNational Institutes of Health Clinical Center · USImmune Deficiency Foundation · USNational Institute of Dental and Craniofacial Research · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with the monogenic immune dysregulatory syndrome autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), which is caused by loss-of-function mutations in the autoimmune regulator (

Indexed as

COVID-19 Drug TreatmentAdultAIRE ProteinAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingCOVID-19FemaleHumansInterferonsMaleMutationPolyendocrinopathies, AutoimmuneSARS-CoV-2Spike Glycoprotein, CoronavirusTranscription FactorsAIRE ProteinAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingbamlanivimabetesevimabInterferonsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Transcription FactorsAIREAPECEDAPS-1bamlanivimab-etesevimabCOVID-19pneumonitistype-1 IFN autoantibodies

Identifiers

PMID34504497
PMCPMC8421855
OpenAlexW3194199981

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.